The Role of Chemotherapy in the Treatment of Hodgkin’s Disease
DOI:
https://doi.org/10.32635/2176-9745.RBC.1968v24n36.4144Palavras-chave:
Doença de Hodgkin/tratamento farmacológico, Doença de Hodgkin/terapia, Antineoplásicos, Antimetabólitos, Quimioterapia Adjuvante, Congressos como AssuntoResumo
Trabalho apresentado no Simpósio Internacional sobre Doença de Hodgkin, realizado no Instituto Nacional de Câncer no Rio de Janeiro — 16 a 20 de Janeiro de 1967. Transcrição da gravação, revisto o original pelo autor.
Downloads
Referências
GOODMAN, L, WINTROBE, M. M., DAMESHEK, W., GOODMAN, M. J., GILMAN, A., and MCLENNAN, M. T.; Nitrogen mustard therapy; use of methylbis (B -chloroethyh) amine hydrochioride and tris(B-chloroethyl)amine hydrochioride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 132; 126, 1946. DOI: https://doi.org/10.1001/jama.1946.02870380008004
JACOBSON, L. O., SPURR, C.L., GUZMAN BARRON, E. S., SMITH, T., LUSHBAUGH, C., and DICK, G. F.: Nitrogen mustard therapy; studies on the effect of methyl-bis(Bis-chloroethyl)-amine hydrochioride on neoplastic diseases and allied lisorders of the hemopoietic system. 1946. DOI: https://doi.org/10.1001/jama.1946.02870400011003
WINTROBE, M. M., MCLENNAN, M. T., and HUGULEY, C. M., Jr.; Clinical experiences with nitrogen mustard therapy. In; Approaches to Tumor Chemotherapy, p. 347. Washington, D. C., Am. Assoe. Advancement Science, 1947.
KARNOFSKY, D. A., BURCHENAL, J. H., ORMSBEE, R. A., CORNMAN, I., and RHOADS, C. P.; Experimental observations on the use of the nitrogen mustards in the treatment of neoplastic diseases. In; Approaches to Tumor Chemotherapy, p. 293. Washington, D. C., Am. Assoe. Advancement Science, 1947.
KARNOFSKY, D. A., BURCHENAL, J. H., ARMISTEAD, G. C., Jr., SOUTHAM, C. M., BERNSTEIN, J. L., CRAVER, L. F., and RHOADS, C. P.: Triethylene melamine in the treatment of neoplastic disease; a compound with introgen-mustard-like activity suitable for oral and intravenous use. A.M.A. Arch. Int. Med. 87; 477, 1951. DOI: https://doi.org/10.1001/archinte.1951.03810040002001
Conference on Hodgkin’s disease, New York, November 25-26, 1957. In; Ann. N. Y. Acad. Science 73; 1-380, 1958.
Hall, T.C.; Choi, O.S.; Abadi, A.; and Krant, M. J. — High dose corticoid therapy in Hodgkin’s Disease and other Lymphomas, Annals of Internal Med. 66; 1144-1153, 1967. DOI: https://doi.org/10.7326/0003-4819-66-6-1144
KARNOFSKY, D. A.; Chemoterapy of Hodgkin’s disease. Câncer 19: 371, 1966. DOI: https://doi.org/10.1002/1097-0142(196603)19:3<371::AID-CNCR2820190310>3.0.CO;2-A
BRUNNER, K. W., and YOUNG, C. W.; A methylhydrazine derivative in Hodgkin’s disease and other malignant tumors; therapeutic and toxic effect studied in 51 patients. Ann. Int. Med. 63; 69, 1965. DOI: https://doi.org/10.7326/0003-4819-63-1-69
KARNOFSKY, D. A.: Meaningful clinical classificiation of therapeutic responses to anticancer drugs. Clin. Pharm. Therapeuties 2; 709, 1961. DOI: https://doi.org/10.1002/cpt196126709
MACDONALD, C. A., and LACHER, M. J.; Oral vinblastine sulfate in Hodgkin’s disease. Clin. Pharm. Therapeuties 7; 534, 1966. DOI: https://doi.org/10.1002/cpt196674534
KARNOFSKY, D. A., MILLER, D. G., and PHILLIPS, R. F.; Role of chemotherapy in the management of early Hodgkin’s disease. Am. J. Roentgenology, Rodium Therap. and Nuclear Med. XC: 968, 1963.
LACHER, M. J., and DURANT, J. R.; Combined vinblastine and chlorambucil therapy of Hodgkin’s disease. Ann. Int. Med. 62; 468, 1965. DOI: https://doi.org/10.7326/0003-4819-62-3-468
TAN, C., TASAKA, H., YU, K. -P., MURPHY, M. L., and KARNOFSKY, D. A.; Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease; clinical evaluation with special reference to childhood leukemia. Câncer 20; 333, 1967. DOI: https://doi.org/10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K
YOUNG, C. W., and KARNOFSKY, D. A.; The necessity of protein synthesis for fever in Hodgkin’s disease. Proc. Am. Assoe. Câncer Res. 8; 75, 1967 (Abstract).
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
